Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/25/2010US20100074863 Anti-infective pyrrolidine derivatives and analogs
03/25/2010US20100074862 N-sulphonylpyrroles and their use as histone deacetylase inhibitors
03/25/2010US20100074861 Compounds having a cyclic moiety and compositions for delivering active agents
03/25/2010US20100074859 Skin care compositions and related methods
03/25/2010US20100074858 Novel iodinated resin manufacturing process and product
03/25/2010US20100074857 Compositions and methods to treat epithelial-related conditions
03/25/2010US20100074856 External preparation composition
03/25/2010US20100074852 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by pbr, cb2, and nk2 receptors
03/25/2010US20100074851 Cosmetic or pharmaceutical composition containing hyaluronic acid
03/25/2010US20100074850 Flavour Modulating Derivative of a Carboxylic Acid and a Purine, Pyrimidine, Nucleoside, or Nucleotide
03/25/2010DE69029370C5 Erythropoietin-Isoformen Erythropoietin isoforms
03/25/2010DE102008048791A1 Neue Kristallform von Calcium-3-Acetylaminopropan-1-sulfonat New crystal form of calcium-3-Acetylaminopropan-1-sulfonate
03/25/2010CA2753338A1 Neutral nanotransporters
03/25/2010CA2746527A1 Rna interference in skin indications
03/25/2010CA2743981A1 Reduced size self-delivering rnai compounds
03/25/2010CA2740530A1 Independent, tobacco addiction-dispelling and detoxifying filter rod and cigarette holder, and process for manufacturing the same
03/25/2010CA2738136A1 A novel iodinated resin manufacturing process and product
03/25/2010CA2738026A1 Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
03/25/2010CA2738018A1 Carboxyethylated cyclodextrin polysulfates useful as medicaments
03/25/2010CA2737835A1 Synergistic combinations of a macrocyclic inhibitor of hcv and a nucleoside
03/25/2010CA2737831A1 Glucoside derivatives and uses thereof as sglt inhibitors
03/25/2010CA2737830A1 Glycoside derivatives and uses thereof
03/25/2010CA2737811A1 Morphinan compounds
03/25/2010CA2737746A1 Coating with antimicrobial agents
03/25/2010CA2737740A1 5-oxazolidin-2-one substituted 1,3,8-triazaspiro [4.5] decan-4-one derivatives useful as orl-1 receptor modulators
03/25/2010CA2737738A1 Heterocyclic carboxamide compounds
03/25/2010CA2737711A1 Bicyclic dihydroimidazolone cgrp receptor antagonists
03/25/2010CA2737683A1 Platinum complex with antitumor activity
03/25/2010CA2737671A1 Composition and use of a long-acting oral bioadhesive endoparasiticide gel based on doramectin
03/25/2010CA2737619A1 Nutritional support of the immune system during anti-cancer treatment
03/25/2010CA2737604A1 Substituted 3-amin0-1-0x0 or thioxo-1,2,5,6,7,8-hexahydr0-2,7-naphthyridine-4-carb0nitriles as selective alpha 2b antagonists
03/25/2010CA2737549A1 Compositions and methods for modulating toll-like receptor activity
03/25/2010CA2737543A1 Composite organic compound powder for medical use and production method and suspension of the same
03/25/2010CA2737527A1 New compounds i
03/25/2010CA2737524A1 Organic compounds for applications in bacterial infections treatment
03/25/2010CA2737496A1 Folate receptor binding conjugates of antifolates
03/25/2010CA2737493A1 Treatment for leukemia and idiopathic aplastic anemia
03/25/2010CA2737484A1 Microencapsulation process with solvent and salt
03/25/2010CA2737483A1 Indole derivatives as crth2 receptor antagonists
03/25/2010CA2737481A1 Stable solid oral dosage co-formulations
03/25/2010CA2737470A1 Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
03/25/2010CA2737463A1 Freeze-dried powder preparation of tetrodotoxin and the producing method thereof
03/25/2010CA2737460A1 Indole derivatives as crth2 receptor antagonists
03/25/2010CA2737431A1 Amino acid derivative
03/25/2010CA2737392A1 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
03/25/2010CA2737380A1 Tabletting excipient based on lactose and cellulose
03/25/2010CA2737355A1 Rapalogs, pharmaceutical compositions, preparation methods and uses thereof
03/25/2010CA2737295A1 Method for the diagnosis of proventricular dilatation disease and kit thereof
03/25/2010CA2737257A1 Pharmaceutical dosage forms comprising poly(.epsilon.-caprolactone)
03/25/2010CA2737199A1 Novel compounds as cannabinoid receptor ligands
03/25/2010CA2737135A1 Methods and kits for treating cluster headache disorders
03/25/2010CA2737099A1 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
03/25/2010CA2737055A1 Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
03/25/2010CA2737038A1 Amide compounds, compositions and uses thereof
03/25/2010CA2736980A1 Aryl-phenyl-sulfonamide-phenylene compounds and their use
03/25/2010CA2736971A1 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
03/25/2010CA2736955A1 Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
03/25/2010CA2736864A1 Stable liquid antibody formulation
03/25/2010CA2736774A1 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
03/25/2010CA2736747A1 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
03/25/2010CA2736707A1 Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
03/25/2010CA2736664A1 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide
03/25/2010CA2736571A1 Azaindole derivatives as crth2 receptor antagonists
03/25/2010CA2736531A1 Process for preparing snuff composition
03/25/2010CA2736438A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer
03/25/2010CA2736018A1 Compositions for treating or delaying the onset of hair loss
03/25/2010CA2735931A1 Amide compounds useful in therapy
03/25/2010CA2735929A1 Hydroxamic acid derivatives useful as antibacterial agents
03/25/2010CA2734402A1 Nicotine-containing granulate
03/25/2010CA2734363A1 Substituted pyrrolidine-2-carboxamides
03/25/2010CA2734349A1 Novel ortho-aminoanilides for the treatment of cancer
03/25/2010CA2733420A1 Use of azaperone for reducing antibiotic usage
03/25/2010CA2732940A1 Use of azaperone for improving growth performance
03/25/2010CA2732893A1 Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers.
03/25/2010CA2710716A1 Cytostatic composition
03/24/2010EP2166095A2 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes in endothelial cells
03/24/2010EP2166094A1 Methods for prolonging the health benefits triggered by a dietary restriction using a sphingosine kinase inhibitor
03/24/2010EP2166019A2 Immunisation against Chlamydia Pneumoniae
03/24/2010EP2166016A1 Phosphoramidate Derivatives of Nucleosides
03/24/2010EP2166015A1 Lincosamide derivative, and antibacterial agent comprising the same as active ingredient
03/24/2010EP2166010A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2166009A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
03/24/2010EP2166008A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2166007A1 Crystalline form of 1-chloro-4-(ß-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
03/24/2010EP2166006A1 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
03/24/2010EP2166003A1 Excitatory amino acid receptor antagonists
03/24/2010EP2166000A1 7-, 8- and 9-substituted tetracycline compounds
03/24/2010EP2165999A1 Formoterol tartrate process and polymorph
03/24/2010EP2165715A1 Therapeutic agent for cancer, and method for treatment of cancer
03/24/2010EP2165712A1 Phenolic extracts of almond peel containing procyanidins, propelargonidins and prodelphinidins, and method for preparation thereof
03/24/2010EP2165711A1 Methods for treating bleeding disorders using sulfated polysaccharides
03/24/2010EP2165710A1 Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
03/24/2010EP2165709A2 Lysine based compounds
03/24/2010EP2165708A2 New pyrazole derivatives as transforming growth factor (tgf) inhibitors
03/24/2010EP2165707A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
03/24/2010EP2165706A1 Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
03/24/2010EP2165705A1 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
03/24/2010EP2165704A1 Use of alverine for the treatment of cutaneous affections
03/24/2010EP2165702A1 Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation
03/24/2010EP2165701A1 Antimicrobial and antiviral compound
1 ... 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 ... 7860